Home
BCDA
BCDA News

Latest BioCardia Inc. (BCDA) News on May 16, 2025

Argus Research

a day ago

Daily – Vickers Top Insider Picks for 05/15/2025

BioCardia Inc (BCDA) Q1 2025 Earnings Call Highlights: Progress in Cardiac Cell Therapy Amid ...

GuruFocus.com

a day ago

BioCardia Inc (BCDA) Q1 2025 Earnings Call Highlights: Progress in Cardiac Cell Therapy Amid ...

BioCardia Reports First Quarter 2025 Business Highlights and Financial Results

GlobeNewswire

2 days ago

BioCardia Reports First Quarter 2025 Business Highlights and Financial Results

Argus Research

2 days ago

Daily – Vickers Top Insider Picks for 05/14/2025

Argus Research

3 days ago

Daily – Vickers Top Insider Picks for 05/13/2025

BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025

GlobeNewswire

7 days ago

BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025

Argus Research

7 days ago

Daily – Vickers Top Insider Picks for 05/09/2025

Argus Research

8 days ago

Daily – Vickers Top Insider Picks for 05/08/2025

Argus Research

9 days ago

Daily – Vickers Top Insider Picks for 05/07/2025

BioCardia Initiates Patient Enrollment at University of Wisconsin at Madison for Ongoing CardiAMP HF II Pivotal Study

GlobeNewswire

10 days ago

BioCardia Initiates Patient Enrollment at University of Wisconsin at Madison for Ongoing CardiAMP HF II Pivotal Study

Argus Research

10 days ago

Daily – Vickers Top Insider Picks for 05/06/2025

Argus Research

11 days ago

Daily – Vickers Top Insider Picks for 05/05/2025

First subject enrolled in BioCardia’s Phase III heart failure therapy trial

Clinical Trials Arena

14 days ago

First subject enrolled in BioCardia’s Phase III heart failure therapy trial

Argus Research

14 days ago

Daily – Vickers Top Insider Picks for 05/02/2025

Biotech Alert: Searches spiking for these stocks today

TipRanks

15 days ago

Biotech Alert: Searches spiking for these stocks today

BioCardia Announces First Patient in Phase 3 Randomized Controlled Double-Blind CardiAMP HF II Clinical Trial of the Company’s Lead Cell Therapy for Treatment of Heart Failure

GlobeNewswire

15 days ago

BioCardia Announces First Patient in Phase 3 Randomized Controlled Double-Blind CardiAMP HF II Clinical Trial of the Company’s Lead Cell Therapy for Treatment of Heart Failure

Argus Research

15 days ago

Daily – Vickers Top Insider Picks for 05/01/2025

Argus Research

16 days ago

Daily – Vickers Top Insider Picks for 04/30/2025

Argus Research

17 days ago

Daily – Vickers Top Insider Picks for 04/29/2025

Argus Research

18 days ago

Daily – Vickers Top Insider Picks for 04/28/2025

Argus Research

21 days ago

Daily – Vickers Top Insider Picks for 04/25/2025

Argus Research

22 days ago

Daily – Vickers Top Insider Picks for 04/24/2025

Argus Research

23 days ago

Daily – Vickers Top Insider Picks for 04/23/2025

Argus Research

24 days ago

Daily – Vickers Top Insider Picks for 04/22/2025

Argus Research

25 days ago

Daily – Vickers Top Insider Picks for 04/21/2025

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 04/18/2025

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 04/17/2025

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 04/16/2025

DSMB recommends continuation of BioCardia’s cell therapy trial for heart failure

Clinical Trials Arena

a month ago

DSMB recommends continuation of BioCardia’s cell therapy trial for heart failure

BioCardia Announces Positive DSMB Review of CardiALLO Allogeneic Cell Therapy for Heart Failure Phase 1/2 Clinical Trial

GlobeNewswire

a month ago

BioCardia Announces Positive DSMB Review of CardiALLO Allogeneic Cell Therapy for Heart Failure Phase 1/2 Clinical Trial

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 04/15/2025

Emory begins enrolment for BioCardia’s trial of ischemic heart failure therapy

Clinical Trials Arena

a month ago

Emory begins enrolment for BioCardia’s trial of ischemic heart failure therapy

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 04/14/2025

MT Newswires

a month ago

BioCardia Says Emory University Enrolling Heart Patients for CardiAMP HF II Trial

BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study

GlobeNewswire

a month ago

BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 04/11/2025

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 04/10/2025

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 04/09/2025

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 04/08/2025

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 04/07/2025

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 04/04/2025

Thomson Reuters StreetEvents

a month ago

Q4 2024 BioCardia Inc Earnings Call

BioCardia Inc (BCDA) Q4 2024 Earnings Call Highlights: Strategic Cost Reductions and Promising ...

GuruFocus.com

a month ago

BioCardia Inc (BCDA) Q4 2024 Earnings Call Highlights: Strategic Cost Reductions and Promising ...

ACC 25: Biocardia’s CardiAMP trial fails but cell therapy potential remains

Clinical Trials Arena

a month ago

ACC 25: Biocardia’s CardiAMP trial fails but cell therapy potential remains

BioCardia’s Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today

GlobeNewswire

2 months ago

BioCardia’s Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today

MT Newswires

2 months ago

BioCardia's Ischemic HF Cell Therapy Trial Reached no 'Statistical Significance' in Primary Composite Efficacy Endpoint

Biocardia Phase 3 CardiAMP-HF Trial of Novel Cardiac Cell Therapy for Ischemic Heart Failure Shows Increased Survival, Decreased Cardiac Events, and Improved Quality of Life at Two Years

GlobeNewswire

2 months ago

Biocardia Phase 3 CardiAMP-HF Trial of Novel Cardiac Cell Therapy for Ischemic Heart Failure Shows Increased Survival, Decreased Cardiac Events, and Improved Quality of Life at Two Years

BioCardia Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.

2 months ago

BioCardia Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

BioCardia Reports 2024 Business Highlights and Financial Results

GlobeNewswire

2 months ago

BioCardia Reports 2024 Business Highlights and Financial Results

What To Expect From BioCardia Inc (BCDA) Q4 2024 Earnings

GuruFocus.com

2 months ago

What To Expect From BioCardia Inc (BCDA) Q4 2024 Earnings

BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025

GlobeNewswire

2 months ago

BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025

Argus Research

2 months ago

Daily – Vickers Top Insider Picks for 03/21/2025

MT Newswires

2 months ago

BioCardia Gets Patent in Japan for Helix Biotherapeutic Delivery System

BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System

GlobeNewswire

2 months ago

BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System

BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions

GlobeNewswire

3 months ago

BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions

BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF)

GlobeNewswire

3 months ago

BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF)

BioCardia upgraded to Buy from Neutral at Alliance Global Partners

TipRanks

4 months ago

BioCardia upgraded to Buy from Neutral at Alliance Global Partners

BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions

GlobeNewswire

4 months ago

BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions

BioCardia Announces Commercial Availability of Morph® DNA™ Steerable Introducer Product Family

GlobeNewswire

5 months ago

BioCardia Announces Commercial Availability of Morph® DNA™ Steerable Introducer Product Family

BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure

GlobeNewswire

5 months ago

BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure

BioCardia Third Quarter 2024 Earnings: US$0.61 loss per share (vs US$1.79 loss in 3Q 2023)

Simply Wall St.

6 months ago

BioCardia Third Quarter 2024 Earnings: US$0.61 loss per share (vs US$1.79 loss in 3Q 2023)

BioCardia Inc (BCDA) Q3 2024 Earnings Call Highlights: Breakthroughs and Challenges in Cardiac ...

GuruFocus.com

6 months ago

BioCardia Inc (BCDA) Q3 2024 Earnings Call Highlights: Breakthroughs and Challenges in Cardiac ...

BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results

GlobeNewswire

6 months ago

BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results

BioCardia to Host Q3 2024 Corporate Update and Financial Results Conference Call on November 13, 2024

GlobeNewswire

6 months ago

BioCardia to Host Q3 2024 Corporate Update and Financial Results Conference Call on November 13, 2024

BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure

GlobeNewswire

7 months ago

BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure

BioCardia Inc (BCDA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

GuruFocus.com

7 months ago

BioCardia Inc (BCDA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

MT Newswires

8 months ago

BioCardia Regains Compliance with Nasdaq Listing Rules for Minimum Equity Levels

BioCardia Regains Full Compliance with Nasdaq Listing Requirements

GlobeNewswire

8 months ago

BioCardia Regains Full Compliance with Nasdaq Listing Requirements

BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules

GlobeNewswire

8 months ago

BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules

MT Newswires

9 months ago

BioCardia Prices $7.2 Million Public Offering

BioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules

GlobeNewswire

9 months ago

BioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules

MT Newswires

9 months ago

Top Midday Gainers

MT Newswires

9 months ago

Sector Update: Health Care Stocks Advance Premarket Thursday

BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family

GlobeNewswire

9 months ago

BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family

MT Newswires

9 months ago

Top Premarket Gainers

MT Newswires

9 months ago

BioCardia Says FDA Cleared Morph DNA Steerable Introducer; Shares Soar Pre-Bell

FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment

GlobeNewswire

9 months ago

FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment

BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results

GlobeNewswire

9 months ago

BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results

BioCardia to Host Q2 2024 Corporate Update and Financial Results Conference Call on August 13, 2024

GlobeNewswire

9 months ago

BioCardia to Host Q2 2024 Corporate Update and Financial Results Conference Call on August 13, 2024

BioCardia Submits for FDA Approval of Morph® DNA™ Steerable Introducer Product Family

GlobeNewswire

10 months ago

BioCardia Submits for FDA Approval of Morph® DNA™ Steerable Introducer Product Family

Patient Enrollment Commenced in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of Ischemic Heart Failure

GlobeNewswire

10 months ago

Patient Enrollment Commenced in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of Ischemic Heart Failure

MT Newswires

10 months ago

BioCardia Receives Patent for Morph DNA Transseptal Delivery

BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application

GlobeNewswire

10 months ago

BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application

CellProthera and BioCardia Collaborate on Successful Phase II Trial of ProtheraCytes™ for the Treatment of Acute Myocardial Infarction

GlobeNewswire

10 months ago

CellProthera and BioCardia Collaborate on Successful Phase II Trial of ProtheraCytes™ for the Treatment of Acute Myocardial Infarction

MT Newswires

a year ago

Top Premarket Decliners

MT Newswires

a year ago

BioCardia Receives Patent for Transendocardial Biotherapeutic Delivery Catheter; Shares Rise Pre-Bell

BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach

GlobeNewswire

a year ago

BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach

Getting smarter: FIA Launches 3-Day Smart Driving Challenge in Samarkand, Powered by Greater Than

PR Newswire

a year ago

Getting smarter: FIA Launches 3-Day Smart Driving Challenge in Samarkand, Powered by Greater Than

3 Major Product Releases at 3Shape Discover Event

PR Newswire

a year ago

3 Major Product Releases at 3Shape Discover Event

GlobeNewswire

a year ago

Fiber Optic Sensors Global Market Forecast & Analysis 2023-2033: Global Fiber Optic Sensors Market to Reach $605.4 Million by 2032 with a CAGR of 6.2%

Simply Wall St.

a year ago

Exploring SEHK Growth Companies With High Insider Ownership: BYD Leads The Way

Business Wire

a year ago

Net Asset Value(s)

AFP

a year ago

Irish, Czechs hold EU vote after Dutch far-right gains

Motley Fool

a year ago

Trade the Nvidia Stock Split? The Tried-and-True Method to Make the Best Profits on the Leading AI Stock

GlobeNewswire

a year ago

GPRC5D Targeting Drugs Market Opportunity and Clinical Trials Insight 2024: Insight on 15+ Drugs in Clinical Trials

MT Newswires

a year ago

BioCardia to Implement 1-for-15 Reverse Stock Split; Shares Fall After Hours

BioCardia Announces Reverse Stock Split

GlobeNewswire

a year ago

BioCardia Announces Reverse Stock Split

GuruFocus.com

a year ago

BioCardia Inc (BCDA) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress Amid ...

BioCardia Reports First Quarter 2024 Business Highlights and Financial Results

GlobeNewswire

a year ago

BioCardia Reports First Quarter 2024 Business Highlights and Financial Results

Most Shareholders Will Probably Find That The Compensation For BioCardia, Inc.'s (NASDAQ:BCDA) CEO Is Reasonable

Simply Wall St.

a year ago

Most Shareholders Will Probably Find That The Compensation For BioCardia, Inc.'s (NASDAQ:BCDA) CEO Is Reasonable

Share on Social Networks: